Company news

Palvella Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

September 17, 2025

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

September 15, 2025

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

September 3, 2025

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

August 28, 2025

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 14, 2025

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

August 7, 2025

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 5, 2025

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

June 30, 2025

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

June 23, 2025

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

June 18, 2025

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

June 9, 2025

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

May 27, 2025

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

May 8, 2025

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

May 5, 2025

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

April 23, 2025

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

April 22, 2025

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology

April 11, 2025

Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

April 4, 2025

Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology

April 2, 2025

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

March 31, 2025

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

March 18, 2025

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

February 25, 2025

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

February 9, 2025

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies

January 9, 2025

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations

January 7, 2025

Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations

November 6, 2024

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

October 16, 2024

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement

July 23, 2024

Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split

April 18, 2024

Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential

March 26, 2024

Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific

August 16, 2023

Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring

July 17, 2023

Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study

June 20, 2023

Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference

May 21, 2023

Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference

May 20, 2023

Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023

May 1, 2023

Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates

March 28, 2023

Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)

January 9, 2023

Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference

November 22, 2022

Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference

November 8, 2022

Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220

October 31, 2022

Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 7, 2022

Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS

August 23, 2022

Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022

July 27, 2022

Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference

June 1, 2022

Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference

May 17, 2022

Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 10, 2022

Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022

May 3, 2022

Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022

February 22, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 24 decks. Every deck is listed under its year.